Inhibition of Wnt/β-Catenin Pathway Overcomes Therapeutic Resistance to Abiraterone in Castration-Resistant Prostate Cancer

Scientists showed that co-treatment with abiraterone and ICG001, a β-catenin inhibitor, overcame therapeutic resistance and significantly inhibited markers of stem cell and cellular proliferation in abiraterone-resistant prostate cancer cells.